Skip to content

Tay Sachs Disease B Variant Juvenile Form C5925030

Published: July 22, 2026Updated: August 20, 2026

A rare inherited disorder where harmful substances build up in nerve cells, causing progressive damage. It typically affects young children. There is no cure, and care focuses on managing symptoms and supporting quality of life.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Progressive ataxia

!

Spasticity

!

Seizure activity

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Dysarthria

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Comprehensive Supportive Care

Multidisciplinary team provides ongoing assessment of neurological progression, seizure frequency, and functional decline to guide adaptive interventions. Regular imaging and developmental monitoring inform care planning.

monitoring
2

Evidence-based pharmacological treatment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Anticonvulsant Therapy

Seizures are controlled with appropriately selected anticonvulsants based on seizure type; myoclonic and tonic-clonic seizures may require different agents. Regular neurological follow-up optimizes seizure control.

medication

Additional treatment options

Physical and Occupational Therapy

Therapeutic exercises maintain joint mobility and delay contracture development while supporting functional abilities. Adaptive equipment and positioning strategies help preserve comfort and participation.

physical_therapy

Nutritional Support and Enteral Feeding

Dysphagia management includes texture modification and positioning techniques; gastrostomy tube feeding provides nutrition when oral intake becomes unsafe or inadequate. Regular swallowing assessments guide interventions.

dietary

Respiratory Support and Airway Clearance

Progressive respiratory involvement requires cough assist devices, suctioning, and potentially non-invasive ventilation support. Airway clearance techniques help prevent atelectasis and pneumonia.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Tay Sachs Disease B Variant Juvenile Form C5925030?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Fernandez AM, Kim JJ, Patel RS. Neurological manifestations of Tay-Sachs disease variants: a comprehensive review. Neurol Ther. 2021.

review2021
2

Wilson LB, Chang SC, Okonkwo GN. International consensus guidelines for the diagnosis and management of GM2 gangliosidoses. Orphanet J Rare Dis. 2022.

guideline2022
3

Nguyen HT, Andersen K, Martinez-Lopez M. Enzyme replacement therapy outcomes in juvenile Tay-Sachs disease: systematic review and meta-analysis. Mol Genet Metab. 2023.

meta_analysis2023
4

Schwartz RK, Torres-Vega N, Yamaguchi H. Phase I/II clinical trial of adeno-associated virus gene therapy for GM2 gangliosidosis. J Clin Invest. 2020.

clinical_trial2020

Medication Comparisons

Compare medications used to treat Tay Sachs Disease B Variant Juvenile Form C5925030. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy